#USA #Providence #Nabsys #CRISPR/Cas9 #Electronic Genome Mapping

Nabsys and CRISPR/Cas9: A Groundbreaking Leap in Electronic Genome Mapping

Nabsys 2.0, LLC, a leading innovator in Electronic Genome Mapping (EGM), has announced a significant publication that merges EGM with the CRISPR/Cas9 gene-editing technology. This pioneering study, titled "CRISPR/Cas9 Optimization Using Electronic Genome Mapping Potential Role for Studying Human Genetic Disease," is led by Dr. John F. Thompson and his team.

Exploring New Horizons in Genome Mapping

This research marks a milestone in genomic analysis by illustrating how CRISPR/Cas9 can be utilized to customize the identification of structural variants through ultra-long DNA molecules. Historically, genome mapping has faced limitations, particularly in addressing specific complex genomic regions. With this new approach, EGM is set to expand its capabilities beyond conventional analyses, thereby overcoming barriers faced in traditional mapping techniques.

Key Applications of the New Study

The publication showcases three significant applications of the combined technologies:

1. Characterization of CRISPR/Cas9 Activity: EGM enables a comprehensive genome-wide assessment of the CRISPR/Cas9 system, particularly focusing on the function of guide RNAs (gRNAs) and protospacer adjacent motif (PAM) sequences. This detailed mapping is crucial for laboratories advancing research in CRISPR-mediated therapies, where the precision of gRNA selection and optimization is vital.

2. Enhancement of EGM Using CRISPR/Cas9: Dr. Thompson's research reveals that CRISPR/Cas9 can effectively augment EGM’s capabilities. By enabling targeted DNA labeling, including label blockage or label insertion, this methodology integrates broad genome analysis with a focus on specified genomic regions. This development is particularly valuable for genetic areas that are hard to investigate using other methods, like cytogenetics or sequencing techniques.

3. Application to Human Genetic Diseases: The study presents a practical application of this approach in examining FXN repeat expansions linked to Friedreich Ataxia. This methodology has the potential to be adapted for other repeat expansion disorders, such as those causing Fragile X syndrome.

A Vision for the Future

Dr. Barrett Bready, Founder and CEO of Nabsys, expressed excitement regarding this groundbreaking study, emphasizing its capacity to generate critical genomic data from ultra-long DNA molecules electronically. This novel approach not only enables the identification of genomic information but also controls where it is generated, paving the way for innovative applications in clinical and translational research.

"A dedicated team of scientists, engineers, and software developers at Nabsys has made this milestone publication possible," said Dr. Bready. "We’re thrilled to introduce these assays to support clinical research with the aim of overcoming challenges in structural variant analysis."

Dr. Alka Chaubey, Chief Medical and Genomics Officer at Nabsys, praised the collaborative efforts of the research team, highlighting the innovative methodology that allows selective modifications. "This breakthrough extends beyond our current understanding of genetic diseases, promising exciting developments in genomics and patient care," she said.

Revolutionary Technology

The OhmX™ Platform, which hosts Nabsys' proprietary EGM technology, stands out by electronically analyzing ultra-long DNA sequences. This advanced technique differentiates itself from traditional systems that rely heavily on lasers and complex optical tools. Instead, it integrates electronic detection with nanofluidics and computational biology in a compact platform, delivering high-resolution genomic insights.

The publication is now available for review as a preprint on bioRxiv, providing researchers with immediate access to these groundbreaking findings. For anyone engaged in genomic research or clinical studies, this innovative leap represents a significant uplift in understanding and addressing genetic disorders effectively.

About Nabsys 2.0, LLC

Nabsys is at the forefront of genomic advancements through a strategic focus on Electronic Genome Mapping technology. With the OhmX™ Platform, Nabsys aspires to revolutionize the domains of cytogenetics and molecular genetics, providing high-resolution insights that facilitate comprehensive structural variation analyses. Based in Providence, Rhode Island, Nabsys continues to expand its impact on genetic research. For further information, you can visit their website at www.nabsys.com.